| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | HGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6470H9986N1714O2018S46 |
| Molar mass | 145545.80 g·mol−1 |
  (what is this?) (verify) | |
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]
Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[2]
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
- ^ a b "Flanvotumab". Adis Insight. Springer Nature Switzerland AG.